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Computer Simulation of a Mathematical Model of
HAART Therapy for HIV- 1 AIDS
Frank Nani and Mingxian Jin
Department of Mathematics and Computer Science
Fayetteville State University
Fayetteville, NC 2830 I , USA
A bstr"ct - A d inicldly pla usible mathe matical model is
coostructed to describe the pa tbo-physiological dyoa mics or
HIV-l induced AIDS during HAART therapy. The model
equations incorporate phySiological interactions between
non-inrected hel per T cells, HIV-I inrected helper T cells,
HIV-I virions in the blood plas ma, HIV-! specific cytotoxic T
cells and dru g molecules or t he HAART protocol. Investigative
computer simulations a rc perrormed to elucidate some
thera peutic sceoarios such as viral a nnihilation and efficacious
HAART therapy. In particula r, some mathematical criter ia
are de rived for thera peutic outco mes such as viral persistence
and viral annibilation.
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1.

INTRODUCTION

In a previous publication [I I] , we presented a
mathematical model describing the patho-physiological
dynamics of the HIV-J virions during the asymptomat ic
latency phase. As the HIV- I virions increase in the blood
plasma, the number density of the CD4"" helper T cells
decrease and the patient eventually develops AIDS.
Currently, the most efficacious method for inducing a
decline in number of HIV- I virions and effecting immune
system reconstitution, is by using highly active antiretroviral
therapy (HAART) [10, 15]. A typical HAART treatment
protocol consists of combinations of protease inhibitors
(Pis), and types of reverse transcriptase inhibitors (RTIs),
which are fabricated as a compact matrix tablet [I , 2, 10]. It
is clinically observed that the HAART treatment regimen
has associated side effects such as gastro-intestinal toxicity,
lipodystrophy, anemia, thrombocytopenia, and renal fai lure

[3, 9, 10].
Several mathematical models have been developed to
describe therapy ofHIV- J induced AIDS (4, 5, 12, 13l The
authors Kirschner and Webb [4, 5] constructed models that
described viral dynamics and drug resistance during
monotherapy of HIV-I infection. Perelson et al.[12]
described the decay characteristics of HIV- l infected
compartments during combination therapy. In [15}, Ye,
Kourtis and Kirschner constructed an elaborate
mathematical model which described the reconstitution of
thymic function in HIV-I patients during HAART therapy.
Recent models, which involve optimal control therapies of
HAART, include those by Stengel {14], Joshi [8], Adams et
al. (I], Caetano and Yoneyama [2], and Joly (7].
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In this paper, an elaborate clinically plausible
mathematical model is constructed to describe HAART
therapy of HlV-I induced AIDS. This model incorporates
constant continuous and periodic transdennal delivery,
Michaelis-Menten drug absorption and clearance kinetics,
and effects of viral latent reservoirs. Mathematical analyses
of the model persistence are perfonned and viral persistence
criteria are calculated. Investigative computer simulations
are performed using hypothetical AIDS patients'
physiological parameters.
The major contribution of the current research is the
fonnulation of robust criteria under which the HJV-I virions
will persist or be annihi lated during the HAART drug
therapy.
II.

PARAMETERS

The model parameters, constants, and variables are
listed as fo llows.
X l:

X2:

Xl:

X4:

the number density of non-HIV-I-infected CD4- helper
T-lymphocytes per unit volume
the number density of HIV- I infected CD4"" helper
T -lymphocytes per unit volume
the number density of HI V- I virions in the blood plasma
per unit volume
the n umber density of HIV- I specific CDS- cytotoxic
T-Iymphocytes per unit volume

x~ :

the concentration of drug molecules of the HAA RT
treatment protocol
Sl: rate of supply of un-infected CD4 + T4-lymphocytes
$ 2: rate of supply of latently infected CD4 ~ T 4-lymphocytes
$ ) : rate of supply of HIV-J virions from macrophage,
monocytes, microglial cells and other lymphoid tissue
different from T4-lymphocytes
$4: rate of supply of CDS" Ta-1ymphocytes from the thymus

D: rate ofHAART drug infusion by transdennal delivery
a" b,: constant associated with acti vation of lymphocytes by
cytokine interleukin-2 (IL-2) (i = 1, 2, 3, 4)
c: rate of HAART drug degradation and excretion
11;:

constant associated with HIV- l infection of CD4helper cells (i = 1, 2, 3)

PI: the

T~

number of HIV-I virions produced per day by
replication and budding in CD4" T4 helper cells
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P2;

rate constant associated with replication and "budding"
of HIV-I in syncytia CD4+ T4 helper cells per day per
microliter {j1I) and released into the blood plasma

A

the number of HIV- I virions produced per day by
replication and "budding" in non-syncytia CD4+ T4
helper cells and released into the blood plasma

1}i:

constant depicting the rate of which HIV-I virions
incapacitate the CDS+ Tg cytotoxic cells (i = I, 2)

(O(h~):Michaelis-Menten

metabolic
rate
associated with HAART drug elimination

reduced gastro-intestinal toxicity [6}. It is also assumed
that elastic Iiposomes are fonnulated and selectively
targeted such as to reduce toxicity to non-HIV - I-infected
CD 4+ T cells (Xl) and CD S+ cytotoxic T cells (x. ).
(ii) The HAART drug is such that each renal excretion and
body clearance rate follows Michaelis-Menten kinetics.
(iii)

g(xj,x

j

= a J xjx je~b'~ 1 forj=o(1,2,4)

)

This function depicts the process of lymphocyte
activation which is mediated by Xl (CD 4) helper T cells.
These cells secrete a lymphokine called interleukin-2.

constants

(o;,J;); Michaelis-Menten
metabolic
rate
constants
associated with HAART drug pharmacokinetics (i =2, 3)

A.

?: cytotoxic coefficient where 0 :5 ?

In this subsection, conditions will be derived under
which solutions curves to the model initial values problem
for HAART AIDS therapy will remain non-negative and
bounded for all t e 9t+.

:5 I (i = 2,3)
q,: constant depicting competition between infected and
un-infected CD4 ~ T4 helper cells (i = 1, 2)

ki : constant depicting degradation, loss of clonogenicity or
"death" (i = I, 2, 3, 4)

e.o: constant depicting death or degradation or removal by
apoptosis (programmed cell death) (i = 1, 2, 3, 4)
K i : constant associated with the killing rate of infected CD4+
T. cells by CDS'" Tg cytotoxic lymphocytes (i = 1,2)
All the parameters are positive.

lnvariance of Non-Negativity ofSolutions

Let to be the time at which the HAART therapy begins.
Set
C j = sup

la ,x jx j e-b,x,

C J = sup

[P2X2Xj

J for j={ 1,2,4}

leU, .r ]

1 ~[ lo. T I

+ PlX 1 ]

(3.2)

here T is the time at which the HAAR T is discontinued.
III.

Also set

MODEL EQUAl!ONS AND ANALYSES

The HIV- I patho-physiological dynamics during
HAART therapy can be modeled using the following system
of non-linear ordinary differential equations:

· - sl +a jx j e

l~,;,x,

x1 -

X· z -

- a l xjx l -Q l x l x 2-

s 2 + a 1 x j x Ze ~b, .,+ a 1 x j x l
-

Xl = S3

K jX ZX 4

-e 10 -

k jx j-e

-Q2X j X2 -

k zX z -

fI jXl

i s

= Df(l)-

CJ" ox s

e10

for

k .x.

-eof{)

_ CJ"2 X 2 X S _ C1" j XJ Xl

i = {1, 2,3, 4,5}

i =

{O,2.3}

i,
Xs

:5 D

where

..10 + x s A2 + x s AJ +xs
I for constant continuous transdermal delivery
f(t) = {I sin n t I for periodic transdennal delivery
x;(to)=x,o

1 for

< S , + C , - k 1 x t - e ,.
< S, + C, - k 2 x 2 - e"
< S ; + C; - k 1x J - e;o
< S, + C , - k 4 x 4 - e 40

i,
x;

- klX l -

A; + Xs
-1}2X1X , -

Xs

(3.3)

The system of non-linear model equations exhibited in (3 . I)
can be convened to the following system of differential
inequalities using (3.2) and (3.3). LetAt) 1.

i,

A2 + Xs
+ P2XZX, + P 1X 1 - a , x 1x 1 -7J j X1X,

I

A, +

=0

~2CJ"2X1X >

s+
' - K 2XZX4
~
a ~ xjx.e -b" "

' O[ t • . T I

jO

';JCJ"lX1X S

· -x.

5, = sup [

Xi

(3.4)

o Q+ 6 2 +6 ,

0

x i (t O ) = x,Q where

i = { I ,2,3,4,5}

The Kamke comparison technique [II ] can be used to
obtain the following system of non-linear inequalities.
for i

(3.1)

The model includes the following clinical improvement:
(i) The drug delivery uses transdermal, stealth-liposome
encapsulated drug delivery, instead of the matrix tablet
fonn because of improved therapeutic efficacy and

5

Xl :S

~

and
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+ y1 e -

r, E

6
'

where

0

R , '" ( 0, 00) and

=0

=0

{I ,2,34 }

0 0 + 0 1 + OJ

j =

{1 ,2.3,4,5}

(3 .5)

The preceding
conclusions.

analyses

lead

to

the

following

i

S +C-e

,

,, '

o

lim sup x , (I):S

,

'0,

x , (t o) =

i= II ,2,3,4}

Ii

where

X 'D

; ={I,2,3,4}

10:s: x , < B,}

A = {(X I' Xl ' X" X.. X, ) E 9\ !

L,

x,

,

x,

, S,

S ! + m,

L,
+ m,

Persistence of AIDS during HAART

In this subsection, criteria will be derived under which
the HIV·l virions will persist under HAAR T therapeutic
protocols, with constant continuOus infusion with rate D .

mi = inf {aixtxie· ··... } where
~ ('• •r)

= sup {alx ) + q1x. + k

lim inr

le

-L , I

f
+ d . e- ."

X I ;:: S I

+ m1 -

E' (O

>

0

Xl

~

SI + m 1 -V I -e zo > 0

L,

l"l

"' I... T)

+ Xs

{PI X ) }

..( .. .T)

,~,a,
+-- -}

+1\ )

"[".T)

.
S + m ! -e 30 >0
lim tnfx;:: l
,
L,
lim inr x. O!: S. + m. - e oo > 0

L,

lim inf x, O!:

C.

l}

L1 = sup{q1 x 1 +k2 +K1
x +
q2(12X2X~}
'1

~ +X,

= inf {PIX1X, + P,x,}

E... > 0
L,

(3.8)

Necessary Criteria/or cure ofAIDS during HAART

One of the desired physiological steady states duri ng
HAART therapy is E- [ XI ' 0, 0, 0, Xs ]. In this
configuration, the HIV·\ infected T4 helper cells (X2), and
HIV-l virions (Xl ), and HIV·l specific cytotoxic Ta cells (X4)
are annihilated by the HAART therapy.
The necessary conditions for the cure of AIDS using
constant continuous transdermal infusion HAART therapy
include:

..( .. .T)

L. = inf

{K1x 1 +17zXj

"(<o r)

L _ in[
' -

'

The system will exhibit pers istence if

i = {1,2,4}

"'(I• •r)

m,

."

L,

In panicular, the solutions are trapped in the region A for all

{

+ d

,~

te9k

L, = sup a )xI + 7]IX.

Ie

(3.7)

lim inf

Xi

'.

L,

'_I,• .TI

V \ = sup

+d

L,

T heorem 1 There exists a TO>O such that for To < t <.,." all
solutions to the HAART model equations (3.1) with initial
values X.o E 9\ ' .. = {x,e 9\ Ix,~ , i=( I ,2,3,4,5)} will eventually
enter the positive invariant region.

Lt

(3.6)

X l;:: Sl+m l - U\-e:!O +dze- L "

Therefore, we have the following theorem.

B.

= {I , 2,3,4,S }

j

...... S I+ m l - e IO

X I ""

B , = sup

e lo

-

Therefore, the following inequalities are obtained:

C3.

where

L\x l

-

X. ;:: s. + m. - L,x, - e oo
x , ;::D - L, x ,

C2. The system is diss ipalive as implied by the inequalities
.

+ ml

i 2 ;:: S !+ m 2 -L!x 2 -V t -e :!O
i , ;:: S 3 + m , - L , X) - e JG

Cl. The solutions to the HAART model are ultimately
bounded.

hmsupx,(t)S;

l ;:: S I

A1

S I +a 1x l e

l}
-\.+x, + A,;+x, + ~+xs

{ (10

...(>0.1")

+k. }

(12 X 1

_t,",

l..

-

1\ \ x

1 - E' IO

S 2 -e %O =0

G"lX

S l -e lO = 0

S. + a.x 1x4 e-t ,I,

Then the following differential inequalities are obtained:

-

k 4 x.

- e 40

= 0
(3.9)
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exhibited in Table I and Table II. It should be stressed that
the data values are estimates and some are from the literature
values listed in [4, 5, II , 12]. Realistic parameters can only
be obtained from actual AIDS patients under clinical
conditions. Several investigative computer simulations are
performed depicting the scenarios of viral persistence and
viral annihilation . Two samples of the simulations are
exhibited in Figure 1 for constant continuous transdermal
infusion and Figure 2 for periodic transdermal infusion.

The sufficient conditions for the cure of AIDS can be
obtained using a Liapunov functional, to guarantee that
E=[ XL ' 0, 0, O. XS J is globally asymptotically stable. This
will be done in a future publ ication.
IV .

SIMULATION RESULTS AND DISCUSS ION

The computer simulations are performed using
hypothetical AIDS patients' configuration ~ and E1, as

TABLE I. Cm';STA>"l" COl'mNUOUS TRANSDER.MAL INFUSION PARAMETRlC CONFIGURATION f\.

S, - 400 /daylpl
0.03/day/ceIUp/
b, - O. I/cclUpl
a, - O.S/daylvirionlpl
k , - O.OOOSfday/pl
q, - O.OOO4Sfday/.uf/ccll
e,o " 1.9 cells/day/pl
X,O "" 200 cellslpl
0 1·

SI-800/daylpl
Ol - 0.03/day/cell/pl
bl - O.004/celUpl
Ql- O.S/daylvi rionlpl
kl - O.OOS/day/pl
q, - O.OOOOllday/.uf/cell
fA - 1.5 virons/C04-'day
K, = O.OOOI/day/pl
e,. - 0.0005 ccllsldaylpl
400 cellslpl

SJ-IOOO/day/pi
A ~ 0.02Svi ronslC04·/daylpl
A= I.S vironslC04-Idt.y
a ) = 0.027 Iday/vi rionlpl
kJ - 0.000 I/day
C;.o - O.OOOI/day
'11- 0.25
G - 0.8S
e. - O.OOI
xJO-SOOcellslpl

x,. -

''''

,'"
''''
''''
lOO

"

.'"

''''

2'"

X,

lOO

'"
\.

0
0

2

l(",o~ lhs)

X,

•

2

0

,

•

I{ ..... alhs)

.'"

200

0

•

200

•

l{m""lI.s)

,

0

•

2

0

l{....Jllhs)

,

•

X,

'"
. 00

,

/

0

'000

'00

0

X,

600

"'"

\

x,.

800

X,

.00

q, - 50 mg/day
Oi '" 50.98 mglday
0; = 10mg/day
Ao - S mglL
A.l - s.s mglL
~ .. 2.5 mglL
~ 1000 ccllslpl

'000

0

,

D - 1000 units

S. '" 0.212 /dt.ylpl
0.03/daylcelUpl
b. - O.Ollcc li/pI
Kl - 0.0024 Id ay/pl
k, - 0.OO8lday/pl
e .... - 0.0002 ccllslday/pl
m - 0.45
XIo - 800 cells/pl
Q, "

0

\

2

•

l(",oalhs)

,

l\

•

Figure I. Simulation results using parametric configuration 1\
TABLE II. PERIODIC TllA.,."'-SOERMAL INFUSION P AM\{ETRlC COlo:FIGURATlON

S, · 400 Iday/pl
01 "" 0.03/day/celVpl
b , "" O.Ol/cell1pl
(II - O.51dt.ylvi riCYf'llpl
k , - 0.OOO5/daylpl
q, - O.OOO4S1day/.uf/cell
e,o - 0.0025 cellslday/pi
XIO " 200 cel1s1p/

Sl "" 800 /day/pi
OJ " 0 .03/day/celUpl
b, - O.OO4/celUpi
a%",0. 5/daylvirionlpl
k, = O.OOS/day/pi

S,

K,'" O.OOOlldaylpl

10 /day/pi
A - 0 .025 vironsIC04-/daylpl
/h - I. S virons/CD4·/dt.y
a, - 0 .027/day/virionlpl
k, " O.OOO l/day
eJO· 0 .000 1 /day
'1, - 0.25
.:, '" 0.85

elO '" 0.0005 cells/day/pl

$J ~ O.OOI

X20 - 4OO cellslpl

XJO - 500 cellslpl

q, .. O.OOOOI /dayl.uf/cell

p. - 1.5 vironsICD4·/day
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P.t

S, - IO/day/pi
= 0 .7S /day/cell/pl
b. - O.Ol/celUpI
Kl - 0.00024/d aylpl
k, " O.OS/day/pl
h. - 0.0002 ce lls/day/pl
m - 0.45
-'#'" 750 cells/pi

Q.

D - 1000 units
q, - 10 ",g/day
o;-tOO",glday
q. - 10 mgJday
Ao~ S mgt!
).,- 10 mgtL
A.,- 2.S nrglL
1500 celis/pi

x,. '"
,-.

x,

'"

'""
""

300
. 00
300

'00

"

l

dlUo"ths~

''''''
3"'"
''''''
''''''
"0

'00

'""

, '"

"

\

"

' 00

,

4

"

,

t{!.oDthsf

• '"

X,

''''''

I

"

• '"

6

t(moDfh$)

X.

''''''
6000
''''''

"00
'00"

)
S

'(mouths)

300

"

"

I~
"

,

It is observed that, in principle, AIDS can be cured. In
particular, using parametric configuration PI for constant
continuous transdermal infusion, the HAART therapy was
unsuccessful because the HIV -I vIrIons increased
dramatically during the therapy, whereas the CD4+ helper T
cells were eliminated.
In Figure 2, using periodic
transdermal infusion with parametric configuration P2, it is
observed that the HAAR T therapy was successful because the

HIV-J virions were annihilated, whereas the CD4"' helper T
cells and the CDS+ HIV - 1 specific cytotoxic T cells
repopulated.
It should be mentioned that there are other simulation
scenarios in which the constant continuous transdennal
infusion were successful and the periodic transdennal
infusion were unsuccessful. Those scenarios will be presented
in a future paper.
SUMMARIZING REMARKS

In this paper, a clinically plausible mathematical model
for HAART therapy is presented which incorporates the
patho-physiological dynamics of HIV- l virions. The novel
transdennal route of drug delivery which minimizes drug
toxicity is utilized. The simulations ofthe model show that for
some given AIDS patients' parametric configurations, it is
possible to cure AIDS. The necessary mathematical criteria
for these scenarios have been presented in the paper. The next
step in the research towards the cure for AIDS is to
investigate whether these results can be achieved in vivo as
well as in the human AIDS patients.
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